HomeCONGRESS

CONGRESS

View Category
Day 1

Estudo EGO-BIOFREEDOM: follow up sequencial longitudinal por OCT de stent sem polímero liberador de biolimus-A9.

Objetivos: O novo stent Biolimus-A9 (BA9) livre de polímero BioFreedom (Biossensores Europe SA, Morges, Suiça) foi estudado...
solaci -
Learn More
Day 3

TOTAL: The thromboaspiration provides no benefit in primary angioplasty

In patients undergoing ST segment elevation myocardial infarction (STEMI) who received primary angioplasty, the strategy of manual...
solaci -
Learn More
Day 3

MATRIX: The radial access reduces events, bivalirudin with mixed results

Two separate works are part of the MATRIX study investigating strategies to reduce bleeding and mortality in...
solaci -
Learn More
Day 3

IMPROVE-IT: The combination simvastatin / ezetimibe reduces post SCA events

This work included 18144 patients from 39 countries that were admitted pursuing an acute coronary syndrome (with...
solaci -
Learn More
Day 3

DANAMI3: Primary Angioplasty to culprit vessel versus multivessel guided by FFR

The aim of this study was to compare the usefulness of primary angioplasty only to culprit vessel...
solaci -
Learn More
Day 3

BEST: Similar mortality among angioplasty with DES (everolimus) and surgery

This observational registry compared the results of myocardial revascularization with angioplasty performed using everolimus-eluting stents in patients...
solaci -
Learn More
Day 1

REGULATE-PCI: REG1 with an unacceptable rate of severe allergic reactions

The aim of this study was to assess treatment with the new anticoagulant Pegnivacogin and its specific...
solaci -
Learn More
Day 1

PROMISE: Functional Test versus tomography for diagnosis of coronary artery disease

This is the first randomized controlled trial to compare the effectiveness of a functional test versus angiography...
solaci -
Learn More